12 Analysts Have This to Say About Genmab
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 12 analysts have published their opinion on Genmab (NASDAQ:GMAB) stock. The company has an average price target of $43.42 with a high of $54.00 and a low of $33.00. The average price target has increased by 13.07% over the past month.
July 24, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's average price target has increased by 13.07% over the past month, indicating a positive sentiment among analysts.
The increase in Genmab's average price target over the past month indicates that analysts are becoming more bullish on the stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100